Lexology February 12, 2025
Private equity investors in health care and life sciences must navigate a complex and shifting landscape influenced by regulatory and policy changes and technological advancements. As private equity investments in the health care industry boomed, the previous administration took an aggressive stance against such investments, and it remains to be seen if the Trump administration will continue these policies. Investors must account for potential regulatory scrutiny and reform, the impact of artificial intelligence (AI) advancements, and supply chain vulnerabilities when evaluating the valuation, compliance, and strategic growth of both new and existing investments. By staying ahead of these trends and understanding the regulatory climate, private equity firms can position themselves to mitigate risks and capitalize on emerging opportunities in this...
Today's Sponsors
Today's Sponsor